Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Benchtop Hematology Analyzer Enables Reduction of Manual Review Rates and Processes

By BiotechDaily International staff writers
Posted on 09 May 2013
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
A new benchtop hematology cellular analysis system provides laboratories with quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Building on its proven cellular analysis technology to further advance and optimize clinical diagnostic laboratories, Beckman Coulter Inc. (Pasadena, CA, USA) introduces the “UniCel DxH 600” Coulter cellular analysis system, a new benchtop hematology analyzer for mid- to high-volume laboratories. The hematology laboratory’s single most important step, and most time consuming, is the manual review. By reducing manual differential rates, the new analyzer frees labs to focus time on quickly and accurately reporting patient results, improving patient health, and reducing the overall cost of care.

With the same technology, user interface, and consumables as the UniCel DxH 800 Coulter analyzer, the UniCel DxH 600 brings superior standardization of results and process to the hematology laboratory, reducing personnel training and simplifying consumable inventory management. (To further enhance standardization, all new DxH 800 analyzers will be installed with the advanced software; and DxH 800 currently in use will be upgraded.)

The UniCel DxH 600 is equipped with robust software—recently cleared by the US Food and Drug Administration (FDA)—that provides new features, enhancements, and research-use parameters. This advanced software also saves time by allowing labs to partially release patient results manually or automatically via decision rules. It also offers users the ability to create and edit decision rules during instrument operation and offers predefined decision rules using Cell Population Data (for research use only; not for use in diagnostic procedures). Additional features include the ability to track workload by the day, hour, and test, as well as providing automatic notification of STAT samples that have not been processed or released within an expected time frame, helping users to report STAT results efficiently.

"This new hematology analyzer has the ability to transform the hematology lab with unparalleled efficiency, revolutionary scalability, and quality of results,” said John Blackwood, senior vice president, Product Management at Beckman Coulter Diagnostics; “The UniCel DxH 600 advances the technology that [...] will change how labs manage their cellular analysis process.”

Related Links:

Beckman Coulter




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.